Serology testing for SARS-CoV-2 is now available for ordering at Michigan Medicine. A separate process for testing and screening of health care workers and Michigan Medicine affiliates will be communicated in the coming weeks.
The serology test detects specific antibodies generated as part of the immune response to SARS-COV-2 infection. Our current test methods detect IgG antibodies, which are usually seen within 2-3 weeks after symptoms begin. Molecular PCR tests, in contrast, detect viral particles present during an active infection.
The serology testing methods being utilized at MM have been independently verified and separately validated by the Clinical Laboratory using over 300 samples. These samples include many potential interferences (autoimmune conditions and other viral infections including seasonal coronaviruses) and samples from patients with PCR-confirmed SARS-CoV-2 with a wide range of time points after symptom onset. The samples we have independently used reflect the types of samples that would be encountered in actual practice. These assays have performed well and demonstrate similar performance to that claimed by manufacturers. In our experience, these tests have greater than 95% sensitivity at greater than two weeks after symptom onset and also demonstrate greater than 98% specificity.
The indications for SARS-CoV-2 serology testing include:
Serology testing is NOT INDICATED as a sole test for patients with acute symptoms, as antibodies are not produced in early stages of infection. Molecular PCR testing remains the appropriate test for diagnosis of acute illness. In addition, there is currently no conclusive evidence that the presence of antibodies confers protection from future or repeat COVID-19 infection.
A positive result indicates detection of IgG antibodies specific to SARS-CoV-2 in the blood, and likely indicates prior exposure and infection by SARS-CoV-2. However, the positive predictive value of a test is due to not only test performance, but also disease prevalence. If the disease prevalence is only 1-2%, a positive screening test result with these assay characteristics would still more likely be a false positive than a true positive result. As such, the meaningfulness of this test relies on testing individuals with a higher likelihood of positivity due to exposures or history of symptomatic illnesses.
A negative result indicates IgG antibodies to SARS-CoV-2 were not detected, which could be due to either absence of prior infection or testing too soon after an infection or in an immunocompromised individual.
Additional information can be found in the linked Fact Sheet.
Written by Dr. Ric Valdez, Dr. Don Giacherio, Dr. Carmen Gherasim, and Dr. David Manthei.
ON THE COVER
Breast team reviewing a patient's slide. (From left to right) Ghassan Allo, Fellow; Laura Walters, Clinical Lecturer; Celina Kleer, Professor. See Article 2014Department Chair |
newsletter
INSIDE PATHOLOGYAbout Our NewsletterInside Pathology is an newsletter published by the Chairman's Office to bring news and updates from inside the department's research and to become familiar with those leading it. It is our hope that those who read it will enjoy hearing about those new and familiar, and perhaps help in furthering our research. CONTENTS
|
ON THE COVER
Autopsy Technician draws blood while working in the Wayne County morgue. See Article 2016Department Chair |
newsletter
INSIDE PATHOLOGYAbout Our NewsletterInside Pathology is an newsletter published by the Chairman's Office to bring news and updates from inside the department's research and to become familiar with those leading it. It is our hope that those who read it will enjoy hearing about those new and familiar, and perhaps help in furthering our research. CONTENTS
|
ON THE COVER
Dr. Sriram Venneti, MD, PhD and Postdoctoral Fellow, Chan Chung, PhD investigate pediatric brain cancer. See Article 2017Department Chair |
newsletter
INSIDE PATHOLOGYAbout Our NewsletterInside Pathology is an newsletter published by the Chairman's Office to bring news and updates from inside the department's research and to become familiar with those leading it. It is our hope that those who read it will enjoy hearing about those new and familiar, and perhaps help in furthering our research. CONTENTS
|
ON THE COVER
Director of the Neuropathology Fellowship, Dr. Sandra Camelo-Piragua serves on the Patient and Family Advisory Council. 2018Department Chair |
newsletter
INSIDE PATHOLOGYAbout Our NewsletterInside Pathology is an newsletter published by the Chairman's Office to bring news and updates from inside the department's research and to become familiar with those leading it. It is our hope that those who read it will enjoy hearing about those new and familiar, and perhaps help in furthering our research. CONTENTS
|
ON THE COVER
Residents Ashley Bradt (left) and William Perry work at a multi-headed scope in our new facility. 2019Department Chair |
newsletter
INSIDE PATHOLOGYAbout Our NewsletterInside Pathology is an newsletter published by the Chairman's Office to bring news and updates from inside the department's research and to become familiar with those leading it. It is our hope that those who read it will enjoy hearing about those new and familiar, and perhaps help in furthering our research. CONTENTS
|
ON THE COVER
Dr. Kristine Konopka (right) instructing residents while using a multi-headed microscope. 2020Department Chair |
newsletter
INSIDE PATHOLOGYAbout Our NewsletterInside Pathology is an newsletter published by the Chairman's Office to bring news and updates from inside the department's research and to become familiar with those leading it. It is our hope that those who read it will enjoy hearing about those new and familiar, and perhaps help in furthering our research. CONTENTS
|
ON THE COVER
Patient specimens poised for COVID-19 PCR testing. 2021Department Chair |
newsletter
INSIDE PATHOLOGYAbout Our NewsletterInside Pathology is an newsletter published by the Chairman's Office to bring news and updates from inside the department's research and to become familiar with those leading it. It is our hope that those who read it will enjoy hearing about those new and familiar, and perhaps help in furthering our research. CONTENTS
|
ON THE COVER
Dr. Pantanowitz demonstrates using machine learning in analyzing slides. 2022Department Chair |
newsletter
INSIDE PATHOLOGYAbout Our NewsletterInside Pathology is an newsletter published by the Chairman's Office to bring news and updates from inside the department's research and to become familiar with those leading it. It is our hope that those who read it will enjoy hearing about those new and familiar, and perhaps help in furthering our research. CONTENTS
|
ON THE COVER
(Left to Right) Drs. Angela Wu, Laura Lamps, and Maria Westerhoff. 2023Department Chair |
newsletter
INSIDE PATHOLOGYAbout Our NewsletterInside Pathology is an newsletter published by the Chairman's Office to bring news and updates from inside the department's research and to become familiar with those leading it. It is our hope that those who read it will enjoy hearing about those new and familiar, and perhaps help in furthering our research. CONTENTS
|
ON THE COVER
Illustration representing the various machines and processing used within our labs. 2024Department Chair |
newsletter
INSIDE PATHOLOGYAbout Our NewsletterInside Pathology is an newsletter published by the Chairman's Office to bring news and updates from inside the department's research and to become familiar with those leading it. It is our hope that those who read it will enjoy hearing about those new and familiar, and perhaps help in furthering our research. CONTENTS
|
MLabs, established in 1985, functions as a portal to provide pathologists, hospitals. and other reference laboratories access to the faculty, staff and laboratories of the University of Michigan Health System’s Department of Pathology. MLabs is a recognized leader for advanced molecular diagnostic testing, helpful consultants and exceptional customer service.